Literature DB >> 27651593

Maternal Serum Aneuploidy Screen and Adverse Pregnancy Outcomes.

Koumudi Godbole1, Aparna Kulkarni2, Asawari Kanade3, Shilpa Kulkarni4, Girish Godbole4, Anuradha Wakankar4.   

Abstract

OBJECTIVE: To find out whether maternal serum screening for fetal chromosomal aneuploidy predicts adverse pregnancy outcomes.
METHODS: A two-year retrospective case-control study was conducted at a tertiary hospital. Pregnant women with a high-risk serum screen but with chromosomally normal fetuses (n = 189) were compared to those with low-risk screen (controls, n = 157) for adverse pregnancy outcomes.
RESULTS: Women with high-risk double marker or combined screen were found to have higher prevalence of LBW [OR 2.56; 95 % CI (1.01-6.53), p < 0.05] and PT [OR 2.93; 95 % CI (1.11-7.65), p < 0.05], while women with high-risk triple screen had higher prevalence of PIH [OR 3.72; 95 % CI (1.23-11.18); p < 0.05], Oligo [OR 4.50; 95 % CI (1.30-15.64); p < 0.05], delivery by C-section [OR 2.51; 95 % CI (1.41-4.47); p < 0.005] as compared to low-risk women. PAPP-A was found to be a significant predictor of birth weight (R (2) = 12.2 %, β ± SE = 0.224 ± 0.069; p < 0.005) and gestational age (R (2) = 4.9 %, β ± SE = 0.613 ± 0.296; p < 0.05). Beta hCG in first and hCG in second trimester predicted oligohydramnios (R (2) = 9.2 %, β ± SE = -0.077 ± 0.025; p < 0.005). The areas under the ROC curves of PAPP-A for LBW and PT were 0.70(p < 0.01) and 0.684 (p < 0.05), respectively.
CONCLUSION: A "high-risk" maternal serum screen with abnormal PAPP-A and/or beta hCG/HCG is associated with adverse pregnancy outcomes and may help identifying women requiring additional fetal surveillance.

Entities:  

Keywords:  Adverse pregnancy outcome; Beta hCG; Maternal serum; PAPP-A

Year:  2016        PMID: 27651593      PMCID: PMC5016434          DOI: 10.1007/s13224-015-0826-2

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  24 in total

1.  Management of abnormal serum markers in the absence of aneuploidy or neural tube defects.

Authors:  William T Schnettler; Michele R Hacker; Rachel E Barber; Sarosh Rana
Journal:  J Matern Fetal Neonatal Med       Date:  2012-03-26

2.  Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an Asian population.

Authors:  T T Hsieh; T H Hung; J J Hsu; W Y Shau; C W Su; F J Hsieh
Journal:  Obstet Gynecol       Date:  1997-06       Impact factor: 7.661

3.  Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.

Authors:  Mohammed-Salleh M Ardawi; Hasan A Nasrat; Abdulrahim A Rouzi; Mohammed H Qari; Mohammed H Al-Qahtani; Adel M Abuzenadah
Journal:  Prenat Diagn       Date:  2007-04       Impact factor: 3.050

4.  Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21.

Authors:  D Wright; H Abele; A Baker; K O Kagan
Journal:  Ultrasound Obstet Gynecol       Date:  2011-09       Impact factor: 7.299

5.  Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU High-Risk Aspirin Study.

Authors:  G S Moore; A A Allshouse; A L Post; H L Galan; K D Heyborne
Journal:  J Perinatol       Date:  2014-12-04       Impact factor: 2.521

6.  First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.

Authors:  K Spencer; N J Cowans; K Avgidou; F Molina; K H Nicolaides
Journal:  Ultrasound Obstet Gynecol       Date:  2008-01       Impact factor: 7.299

Review 7.  Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis.

Authors:  Rachel K Morris; Jeltsje S Cnossen; Marloes Langejans; Stephen C Robson; Jos Kleijnen; Gerben Ter Riet; Ben W Mol; Joris A M van der Post; Khalid S Khan
Journal:  BMC Pregnancy Childbirth       Date:  2008-08-04       Impact factor: 3.007

Review 8.  Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials.

Authors:  P M Villa; E Kajantie; K Räikkönen; A-K Pesonen; E Hämäläinen; M Vainio; P Taipale; H Laivuori
Journal:  BJOG       Date:  2012-11-06       Impact factor: 6.531

9.  Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis.

Authors:  S Roberge; K H Nicolaides; S Demers; P Villa; E Bujold
Journal:  Ultrasound Obstet Gynecol       Date:  2013-05       Impact factor: 7.299

Review 10.  Biological functions of hCG and hCG-related molecules.

Authors:  Laurence A Cole
Journal:  Reprod Biol Endocrinol       Date:  2010-08-24       Impact factor: 5.211

View more
  4 in total

1.  Association Between Serum Markers Used in the Routine Prenatal Screening with Pregnancy Outcomes: A Cohort Study.

Authors:  Zohreh Alizadeh-Dibazari; Zahra Alizadeh-Ghodsi; Azita Fathnezhad-Kazemi
Journal:  J Obstet Gynaecol India       Date:  2021-08-06

Review 2.  Biomarkers for Macrosomia Prediction in Pregnancies Affected by Diabetes.

Authors:  Sofia Nahavandi; Jas-Mine Seah; Alexis Shub; Christine Houlihan; Elif I Ekinci
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-31       Impact factor: 5.555

3.  Predictability of Macrosomic Birth based on Maternal Factors and Fetal Aneuploidy Screening Biochemical Markers in Hyperglycemic Mothers.

Authors:  Junguk Hur; Jinho Yoo; Dayeon Shin; Kwang-Hyun Baek; Sunwha Park; Kyung Ju Lee
Journal:  Int J Med Sci       Date:  2021-05-13       Impact factor: 3.738

4.  False-Positive Maternal Serum Screens in the Second Trimester as Markers of Placentally Mediated Complications Later in Pregnancy: A Systematic Review and Meta-Analysis.

Authors:  Christy L Pylypjuk; Joel Monarrez-Espino
Journal:  Dis Markers       Date:  2021-06-04       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.